WEBULL
WebtradeDownload

Merck (MRK) Wins FDA Approval For First Oral PCSK9 Cholesterol Drug

Simply Wall St · 4d ago
  • Merck (NYSE:MRK) has received US FDA approval for LIPFENDRA, the first oral PCSK9 inhibitor for cholesterol management.
  • The drug targets adults with hypercholesterolemia who need additional LDL cholesterol lowering beyond existing therapies.
  • LIPFENDRA introduces an oral option in a treatment class that has so far been dominated by injectable PCSK9 therapies.

This shift toward oral and AI supported drug development in cardiometabolic care points to a broader trend that investors may want to explore through 38 healthcare AI stocks.

NYSE:MRK Earnings & Revenue Growth as at Sep 2026
NYSE:MRK Earnings & Revenue Growth as at Sep 2026

Merck is a global pharmaceuticals company headquartered in GB, with a reported market value of about $364.5b, and this approval slots into its broader role as a diversified healthcare group developing treatments across multiple therapeutic areas. For cardiometabolic investors, it shows how a large established player is still working on new drug formats in a mature disease category.

2 things going right for Merck that this headline doesn't cover.

Merck’s oral PCSK9 move and the push to broaden growth drivers

Merck’s Narrative is built on turning a much larger late-stage pipeline into multiple growth drivers that can rebalance the business away from single-product risk. LIPFENDRA fits that premise by adding a cardiometabolic product launch alongside the high-profile oncology and vaccines franchises.

With its acquisition and licensing strategy, Merck has nearly tripled its late phase pipeline since 2021, which is expected to have a potential commercial opportunity of over $50 billion by the mid 2030s, driving earnings growth...

Read the full Merck narrative to see the case behind these numbers.

LIPFENDRA feeds directly into the Narrative’s claim that Merck can bring more than 20 new growth drivers to market. It adds a non-oncology product where incumbents like Amgen and Sanofi have focused on injectables, and it supports the idea that Merck can use R&D depth to enter competitive categories with differentiated formats.

At the same time, this approval tests whether Merck’s expanded pipeline can offset risks flagged in the Narrative, such as KEYTRUDA’s eventual loss of exclusivity and global pricing pressure. The commercial outcome for an oral PCSK9 in a crowded cholesterol market will be an early indicator of how much of that planned US$50b opportunity is practically reachable.

For investors trying to make sense of product headlines like LIPFENDRA, a clear Merck Narrative helps turn scattered news into a coherent view of risk, reward and execution priorities.To ensure you're always in the loop on how the latest news impacts the investment narrative for Merck, head to the community page for Merck to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.